BeiGene

Youtube Subscribe

Open: 230.8 Close: 232.6 Change: 1.8

You're running out of time to find out about BeiGene using an AI.

This document will help you to evaluate BeiGene without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about BeiGene are: BeiGene, Capital, price, Foundation, Management, stock, offer, and the …

Concept Map

Semantic Network

Stock Summary

BeiGene, Ltd. develops and commercializes oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; Tislelizumab to treat solid tumor and blood cancers. The company is also developing.

Today's Summary

BeiGene will offer access to Brukinsa (zanubrutinib) in 29 low and middle-income countries between 2023 and 2026.

Today's News

BeiGene will offer access to Brukinsa (zanubrutinib) in 29 low and middle-income countries between 2023 and 2026. The Max Foundation and the BeiGene Foundation have partnered with global technology company BeiGene. BeiGene raised a total of $177M. Investors of BeiGene include Get Finance Holdings, Hillhouse Capital Management, Amgen, CITIC Capital, Rock Springs Capital and 7 more. BeiGene hiring Manager/Senior Manager, Biomarker and Translational Science Portfolio Management in San Mateo, California, United States. Beigene Ltd (ADR) stock price, history, target price and what caused it to recently rise, lets take a look at some background. BeiGene (BGNE) stock price today, news, quotes, faqs and fundamentals. BeiGene posted 2.4 billion yuan net loss in first quarter of 2023.

Stock Profile

"BeiGene, Ltd., a biotechnology company, develops and commercializes oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; Tislelizumab to treat various solid tumor and blood cancers; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumor malignancies; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company is also developing Zanubrutinib to treat B-cell malignancies; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Ociperlimab for treating solid tumors, cervical cancer, and NSCLC; Surzebiclimab, BGB-A445, BGB-15025, Lifirafenib, BGB-24714, and BGB-B167 to treat solid tumors; BGB-10188 for treating solid tumors, B-cell lymphoid malignancies, and B-cell malignancies; BGB-11417 to treat R/R chronic lymphocytic leukemia/ small lymphocytic lymphoma, R/R mantle cell lymphoma, Mature B-cell malignancies, Myeloid malignancies, and R/R multiple myeloma; BGB-16673 for B-cell malignancies; and BGB-23339 for Inflammation and immunology. The company has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Enlivex Therapeutics Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands."

Keywords

The game is changing. There is a new strategy to evaluate BeiGene fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about BeiGene are: BeiGene, Capital, price, Foundation, Management, stock, offer, and the most common words in the summary are: beigene, news, sport, company, report, opinion, brukinsa, . One of the sentences in the summary was: BeiGene will offer access to Brukinsa (zanubrutinib) in 29 low and middle-income countries between 2023 and 2026.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #beigene #news #sport #company #report #opinion #brukinsa.

Read more →

Youtube Subscribe

---